Calidi Biotherapeutics, Inc. 8K

Calidi Biotherapeutics filed a Form 8-K to report Q2 2026 financial results and provide pipeline, regulatory, and governance updates, including positive FDA pre-IND feedback on CLD-401, new RedTail platform data, cost reductions, and a new board member.

Calidi Biotherapeutics, Inc. reported its financial results for the second quarter ended June 30, 2026, highlighting a narrowed net loss driven by a 48% reduction in general and administrative expenses, continued investment in R&D, and a cash balance of $4.1 million, while also providing business updates including positive pre-IND feedback from the U.S. FDA on its lead RedTail platform candidate CLD-401 supporting a planned first-in-human trial with initial patient dosing targeted for Q1 2027, presentation of new preclinical data for CLD-401 and CLD-501 at the 2026 ASCO Annual Meeting, advancement of its in situ T-cell engager programs, and the strengthening of its Board of Directors with the appointment of industry veteran Corsee Sanders, Ph.D.

Filing Facts

CIK

1855485

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-037840

Alert Tier

6